014570.Kq
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a strong liquidity position, with a current ratio of 8.33, indicating a high ability to meet short-term obligations. Its cash and equivalents amount to KRW 4,847,182,630, and free cash flow stands at KRW 6,270,756,990, supporting operational flexibility and potential for reinvestment. The price-to-book ratio of 0.47 suggests the company is trading at a discount relative to its book value, which may reflect market skepticism or undervaluation.
Profitability metrics show a return on equity of 7.84% and a return on assets of 6.9%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The gross profit margin is 42.56% (KRW 26,600,531,410 / KRW 62,508,834,680), and the operating margin is 11.07% (KRW 6,913,176,840 / KRW 62,508,834,680), indicating moderate efficiency in converting revenue into profit. These figures suggest the company is performing in line with or slightly below the industry median for profitability, depending on the specific cohort.
The company's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risk. However, the absence of disclosed revenue concentration suggests a potentially diversified revenue base, which is a positive sign for risk mitigation.
The company's growth trajectory is not explicitly outlined in the available data, but the operating cash flow of KRW 13,109,993,640 and free cash flow of KRW 6,270,756,990 indicate a strong cash-generating ability. The capital expenditure of KRW -475,045,360 suggests a reduction in investment in physical assets, which may reflect a focus on cost optimization or a mature business stage.
Risk factors are minimal, with no immediate filing-based liquidity or dilution flags detected. The dilution potential is low, and the company's debt-to-equity ratio is 0.0, indicating no long-term debt and a strong equity position. The absence of dilution risk and the low liquidity risk contribute to a stable financial profile.
Recent events, including filings and transcripts, do not indicate any material changes in the company's operations or financial condition. The company appears to be maintaining a steady course without significant disruptions or strategic shifts.
- The company has a strong liquidity position with a current ratio of 8.33 and substantial free cash flow.
- Profitability metrics are moderate, with a return on equity of 7.84% and a return on assets of 6.9%.
- The company is trading at a price-to-book ratio of 0.47, suggesting potential undervaluation.
- There is no immediate liquidity or dilution risk, and the debt-to-equity ratio is 0.0.
- The company's growth trajectory is supported by strong operating and free cash flow.
- The absence of revenue concentration data suggests a potentially diversified revenue base.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 014570.KQ Market data — financials · 2026-05-26